Biodesix Statistics

Total Valuation

Biodesix has a market cap or net worth of $56.23 million. The enterprise value is $108.98 million.

Market Cap	56.23M
Enterprise Value	108.98M

Important Dates

The last earnings date was Thursday, August 7, 2025, after market close.

Earnings Date	Aug 7, 2025
Ex-Dividend Date	n/a

Share Statistics

Biodesix has 146.63 million shares outstanding. The number of shares has increased by 48.04% in one year.

Current Share Class	146.63M
Shares Outstanding	146.63M
Shares Change (YoY)	+48.04%
Shares Change (QoQ)	+0.07%
Owned by Insiders (%)	50.75%
Owned by Institutions (%)	27.22%
Float	62.05M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	0.74
Forward PS	0.80
PB Ratio	49.40
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	1.42
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.14, with a Debt / Equity ratio of 64.56.

Current Ratio	2.14
Quick Ratio	1.86
Debt / Equity	64.56
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-4.60

Financial Efficiency

Return on equity (ROE) is -219.68% and return on invested capital (ROIC) is -24.48%.

Return on Equity (ROE)	-219.68%
Return on Assets (ROA)	-20.81%
Return on Invested Capital (ROIC)	-24.48%
Return on Capital Employed (ROCE)	-46.70%
Revenue Per Employee	$280,425
Profits Per Employee	-$150,469
Employee Count	273
Asset Turnover	0.75
Inventory Turnover	11.61

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -76.18% in the last 52 weeks. The beta is 0.98, so Biodesix's price volatility has been similar to the market average.

Beta (5Y)	0.98
52-Week Price Change	-76.18%
50-Day Moving Average	0.33
200-Day Moving Average	0.80
Relative Strength Index (RSI)	51.73
Average Volume (20 Days)	1,553,151

Short Selling Information

The latest short interest is 3.92 million, so 2.67% of the outstanding shares have been sold short.

Short Interest	3.92M
Short Previous Month	4.28M
Short % of Shares Out	2.67%
Short % of Float	6.32%
Short Ratio (days to cover)	3.44

Income Statement

In the last 12 months, Biodesix had revenue of $76.56 million and -$41.08 million in losses. Loss per share was -$0.28.

Revenue	76.56M
Gross Profit	60.30M
Operating Income	-33.89M
Pretax Income	n/a
Net Income	-41.08M
EBITDA	-28.08M
EBIT	-33.89M
Loss Per Share	-$0.28

Full Income Statement

Balance Sheet

The company has $20.73 million in cash and $73.47 million in debt, giving a net cash position of -$52.74 million or -$0.36 per share.

Cash & Cash Equivalents	20.73M
Total Debt	73.47M
Net Cash	-52.74M
Net Cash Per Share	-$0.36
Equity (Book Value)	1.14M
Book Value Per Share	0.01
Working Capital	17.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$29.94 million and capital expenditures -$1.20 million, giving a free cash flow of -$31.13 million.

Operating Cash Flow	-29.94M
Capital Expenditures	-1.20M
Free Cash Flow	-31.13M
FCF Per Share	-$0.21

Full Cash Flow Statement

Margins

Gross margin is 78.77%, with operating and profit margins of -44.27% and -53.66%.

Gross Margin	78.77%
Operating Margin	-44.27%
Pretax Margin	-53.66%
Profit Margin	-53.66%
EBITDA Margin	-36.67%
EBIT Margin	-44.27%
FCF Margin	n/a

Dividends & Yields

Biodesix does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-48.04%
Shareholder Yield	-48.04%
Earnings Yield	-73.05%
FCF Yield	-55.36%

Analyst Forecast

The average price target for Biodesix is $1.75, which is 356.32% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$1.75
Price Target Difference	356.32%
Analyst Consensus	Strong Buy
Analyst Count	5
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Biodesix has an Altman Z-Score of -6.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-6.75
Piotroski F-Score	3